KODK : The sleeping giant.
Hello All. Here is my analysis that is not so far fetched.
Pros:
1. Partnership with microsoft.
2. Solid institutions bought in December 2020
3. Pharmaceutical Division pending
4. Low float count in available shares
5. Multiple failed breakouts but solid consolidation
6. Potential Loan coming from the Federal Government to kick start Pharmaceutical Division
CATALYST: Short interest is between 18% - 24%.
I am long with two short term targets. $17 & $20. Not to mention, calls are super bullish for this month all the way through April. Hang tight and be patient.
Pros:
1. Partnership with microsoft.
2. Solid institutions bought in December 2020
3. Pharmaceutical Division pending
4. Low float count in available shares
5. Multiple failed breakouts but solid consolidation
6. Potential Loan coming from the Federal Government to kick start Pharmaceutical Division
CATALYST: Short interest is between 18% - 24%.
I am long with two short term targets. $17 & $20. Not to mention, calls are super bullish for this month all the way through April. Hang tight and be patient.
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。